alopecia areata
Conditions
Interventions
Tissue sample cohort of alopecia areata patients (Obtained tissue samples from alopecia areata-affected skin and normal skin, and track treatment efficacy.):None
Retrospective overall cohort of alopecia areata patients:None
Sponsors
Department of Dermatology, Huazhong University of Science and Technology Tongji Medical College Tongji Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Aged 18–60 years, any sex. (2) Clinically diagnosed with alopecia areata by two board-certified dermatologists (associate chief physician or above) according to the Chinese Guidelines for the Diagnosis and Treatment of Alopecia Areata. (3) SALT score >= S2 (>= 25% scalp hair loss). (4) Stratified by disease activity: Progressive stage:new or enlarging patches within the past 3 months, positive hair-pull test at lesion margins (>= 6 vellus or telogen hairs), and SALT increased by >= 10% from baseline. Stable stage: no evident progression within the past 6 months, no new or enlarging patches, negative hair-pull test, and SALT fluctuation <5%. (5) Able and willing to comply with required clinical assessments and sample collection.
Exclusion criteria
Exclusion criteria: (1) Age 60 years. (2) Women who are pregnant, breastfeeding, or planning pregnancy. (3) Concomitant conditions that may cause hair loss (e.g., androgenetic alopecia, cicatricial alopecia, syphilitic alopecia). (4) Concomitant autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, vitiligo), systemic inflammatory diseases, active infection, or a history of malignancy. (5) Any systemic therapy within 3 months prior to enrollment, including corticosteroids, immunosuppressants (e.g., methotrexate, cyclosporine), or JAK inhibitors. (6) Any topical treatment applied to the intended scalp sampling area within 1 month prior to enrollment, including topical corticosteroids, minoxidil, or topical immunotherapy. (7) Known allergy to local anesthetics or any reagents used in the study. (8) Any other condition deemed by the investigator to make participation unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cellular composition and transcriptomic profiles of lesional vs control scalp tissue by single-cell RNA sequencing; | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment efficacy;Dermoscopy features;Baseline SALT score;Demographic characteristics; | — |
Countries
China
Contacts
Public ContactYong Zhang
Huazhong University of Science and Technology Tongji Medical College Tongji Hospital
Outcome results
None listed